Sofosbuvir & Velpatasvir

Sovihep V

Indication:

What do you mean by SOVIHEP V Tablet PC?
SoviHep V medication combination and sofosbuvir velpatasvir. This medicine works to reduce the amount of hepatitis C virusneeded in your body, thus contributing to your immune system against infection and may help your liver to restore what is using SOFOSBUVIR 400 MG and 100 VELPATASVIR mg tablets Agent Zydus Heptiza Sofosbuvir Velpatasvir and liver for the treatment of chronic (long term) hepatitis C virus infection.

Sometimes it may use another antiviral drug triazole nucleoside indium). SOFOSBUVIR VELPATASVIR Common side effects: Common side effects SoviHep V may include: headache, fatigue; nausea, diarrhea; or sleep problems (insomnia). Call your doctor if you have: slow heartbeat; weaker or lighter breathing; or lower red blood cell skin pale, weak, fast heart rate, fault concentration.

This is not a complete list of all the side effects that may occur. If you have questions about the side effects, please contact your health care provider. Call your doctor's medical advice about the side effects.


Brand name: Sovihep V

Active Ingeridents: Sofosbuvir-400Mg-Velpatasvir-100Mg

Company Name: Zydus

Package: 28 tabs/bottle

Strength : 400 MG & 100 MG

Sofosbuvir Mechanism of action:

Sofosbuvir Plus Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir plus velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

Dosage and Administration:

Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg plus velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.

  • Renal Impairment: For patients with mild to moderate renal impairment, no dosage adjustment of sofosbuvir-velpatasvir is recommended. There are insufficient data regarding the safety and efficacy of sofosbuvir-velpatasvir in patients with severe renal impairment (eGFR less than 30 ml/min/1.73m2) or end-stage renal disease requiring hemodialysis. Accordingly, no dosage recommendation has been given for patients with severe renal impairment or end-stage renal disease requiring dialysis.
  • Hepatic Impairment: For patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C), no dosage adjustment for sofosbuvir plus velpatasviris recommended. For patients with decompensated cirrhosis who are receiving sofosbuvir-velpatasvir and ribavirin, clinical and laboratory monitoring is recommended.

Store:

Sofosbuvir With Velpatasvir room temperature away from moisture and heat.

Warning

Sofosbuvir plus Velpatasvir is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofosbuvir Side effects:

The most common Side effects (≥10%, all grades) with Sofosbuvir plus Velpatasvir were headache and fatigue; and when used with Ribavirin in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Precaution:

  • Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir plus Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Sofosbuvir plus Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.